Expression and Significance of CD123 and CD96 in Myelodysplastic Syndrome

Abstract

Abstract. Objective: To explore the relationship between the expression of CD123 and CD96 and prognosis in MDS. Methods: 89 MDS patients and 20 controls are enrolled. The patients are grouped by the risk. All participants are detected by bone marrow biopsy. Mononuclear cells are extracted, CD34+CD38-CD123+ and CD34+CD38-CD96+ cells are counted by flow cytometry. Expression of the two types of cells in control group, observation group and its subgroups are analyzed. Results: MDS patients display significantly larger proportion of CD34+ cells and CD34+CD38-cells than that of controls (P<0.05) and the proportion increases with the risk. In the low-and middle-risk group, the rates of complete remission (CR ) and partial remission (RR) are significantly higher in CD123-CD96-cells than that in CD123+CD96+ cells. In the middle-and high-risk patients group, RR is significantly higher in CD123-cells than that in CD123+ cells (P<0.05) and CR is significantly higher in CD96-cells than that in CD96+ cells (P<0.05). Conclusion: The differentiation of CD34+ cells in bone marrow of MDS patients is abnormal, with the high expression of CD123 and CD96 cells. These findings might partly explain the cause of MDS patients with hematopoietic stem cells malignant clone.